Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results


Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024.

Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2024 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations.

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's business. The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture, and academic research.

Follow us on LinkedIn | X | YouTube | Instagram


These press releases may also interest you

at 20:11
Report with the AI impact on market trends - The global online therapy services market size is estimated to grow by USD 64.09 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  53.9%  during the forecast...

at 20:02
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce, further to its news release of January 10, 2025, an extension of its previously announced non-brokered private placement offering of units of the Company (the...

at 19:25
The new year brings new beginnings for 26Health and its patients with the grand opening of a newly renovated facility in Orlando. "We...

at 19:00
CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity in 2024 after licensing ivaltinostat from CG Invites. The company has since been conducting various...

at 18:00
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting Alluminoxtm platform-based photoimmunotherapy, today announced the initiation of its global multi-regional Phase 3 clinical trial...

at 17:46
Andlauer Healthcare Group Inc. ("AHG" or the "Company") will release its 2024 fourth quarter and year-end financial results after market close on Wednesday, February 26, 2025. Michael Andlauer, Chief Executive Officer, and Peter Bromley, Chief...



News published on and distributed by: